Holmes et al. [102] investigated the augmentative effects of Saponinum album saponins on Saporin-based ITxs constructed with antibodies directed against CD7, CD19, CD22, CD38 and CD71 on three different human leukemia or lymphoma cell lines, but found considerable cell line and target molecule variation on the extent of augmentation observed, ranging from just 174-fold to greater that 31.5 million-fold for Daudi lymphoma cells targeted via CD19 antigen. Here, TFRC is linked to lymphoma.